The most common mutation seen in non-small cell lung cancer (NSCLC), accounting for approximately 85% of all lung cancer types, is in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) (Testa et al., 2018). This evidence concerns the gene EGFR and lung cancer.